Bronchiolitis

Disclaimer: This information is for educational and informational purposes only and does not constitute medical advice. It is intended to support, not replace, the professional judgment of healthcare providers. Always consult with a qualified healthcare professional for diagnosis and treatment of any medical condition. Clinical decisions must be based on individual patient circumstances, current guidelines, and professional medical judgment.

Overview

• Definition: Bronchiolitis is a common acute inflammatory illness of the small airways (bronchioles) that affects infants and young children, most commonly in the first two years of life. It is typically caused by a viral infection, leading to edema, mucus production, and cellular debris, which obstruct the small airways.
• Epidemiology:
  • Incidence: It is the leading cause of hospitalization in infants, affecting nearly all children by age 2-3 years. Approximately 2-3% of infants are hospitalized with bronchiolitis annually.
  • Age: Primarily affects infants <12-24 months of age, with peak incidence between 2-6 months. Severity is generally inversely related to age.
  • Seasonality: Highly seasonal, typically occurring during fall, winter, and early spring months, coinciding with peak respiratory virus activity (especially Respiratory Syncytial Virus - RSV).
  • Etiology: While RSV is the most common cause (50-80% of cases), other viruses include rhinovirus, human metapneumovirus, parainfluenza virus, adenovirus, and influenza virus. Co-infections with multiple viruses are common.
• Classification: Primarily classified as acute viral bronchiolitis. No widely accepted subtypes based on severity, though clinical scores are used to assess severity (e.g., Bronchiolitis Severity Score).

Pathophysiology

• Mechanism:
  1. Viral Entry and Replication: Viruses typically infect nasopharyngeal epithelial cells and then spread to the lower respiratory tract, primarily targeting ciliated bronchial and bronchiolar epithelial cells.
  2. Inflammation and Necrosis: Viral replication leads to direct cellular injury, necrosis of epithelial cells, and a robust inflammatory response. This causes submucosal edema, increased mucus production, and infiltration by inflammatory cells (lymphocytes, neutrophils, macrophages).
  3. Airway Obstruction: The combination of epithelial cell necrosis, excessive mucus, inflammatory exudate, and submucosal edema narrows the small airways. Sloughed epithelial cells and debris can form plugs, leading to partial or complete obstruction.
  4. Air Trapping and Atelectasis: Partial obstruction leads to "ball-valve" effects, trapping air distal to the obstruction during expiration and causing hyperinflation. Complete obstruction can lead to distal atelectasis.
  5. V/Q Mismatch: Areas of atelectasis or hypoventilation, combined with preserved perfusion, lead to ventilation-perfusion mismatch, resulting in hypoxemia. Increased work of breathing contributes to respiratory distress.
• Risk Factors: For severe disease and hospitalization:
  • Age: Young age (<12 weeks, especially <6 weeks)
  • Prematurity: Gestational age <37 weeks
  • Underlying Cardiopulmonary Disease: Congenital heart disease (especially hemodynamically significant), chronic lung disease of prematurity (bronchopulmonary dysplasia).
  • Immunodeficiency: Primary or secondary immunodeficiencies.
  • Neuromuscular Disorders: Impaired airway clearance.
  • Environmental Factors: Exposure to tobacco smoke (in utero or passive), crowded living conditions, high sibling count, childcare attendance.
  • Others: Male gender, low birth weight, lack of breastfeeding.
• Protective Factors:
  • Breastfeeding: Provides antibodies and protective factors, reducing incidence and severity.
  • Full-term Birth: Reduces risk of immature lung development.
  • Good Hygiene: Handwashing, avoiding sick contacts.

Clinical Presentation

Signs and Symptoms

Symptoms typically evolve over 2-5 days and peak on days 3-5. - Cardinal Features: * Rhinorrhea: Clear nasal discharge, often profuse. * Cough: Initial dry cough progressing to wet, paroxysmal cough. * Wheezing: High-pitched expiratory sounds, often audible without a stethoscope. * Tachypnea: Increased respiratory rate. * Fever: Low-grade fever common; high fever can suggest bacterial co-infection. * Poor Feeding: Due to tachypnea and nasal congestion, leading to dehydration. - Early Signs: * Upper respiratory tract symptoms (coryza, nasal congestion, mild cough) for 1-3 days. * Irritability. * Decreased appetite. - Advanced Signs: * Increased work of breathing: Nasal flaring, grunting, intercostal/subcostal/supraclavicular retractions. * Cyanosis (circumoral or generalized), indicating significant hypoxemia. * Apnea (especially in infants <2-3 months, premature infants, or those with comorbidities), often preceding other signs of respiratory failure. * Lethargy, decreased responsiveness. * Signs of dehydration (decreased wet diapers, sunken fontanelle, dry mucous membranes, poor skin turgor). - Atypical Presentations: * Apnea as presenting symptom: Common in very young infants (<6 weeks) and premature infants, without prominent respiratory distress. * Minimal respiratory signs: Some infants, especially those with underlying conditions, may present with subtle signs or only hypoxemia.

Physical Examination

• Inspection:
  • Respiratory Distress: Tachypnea (respiratory rate >60 breaths/min common in infants), nasal flaring, subcostal/intercostal/suprasternal retractions, head bobbing (severe).
  • Cyanosis: Perioral or central, indicating hypoxemia.
  • General Appearance: Alertness, hydration status (sunken fontanelle, dry mucous membranes, decreased tears).
  • Cough: Often productive or paroxysmal.
  • Color: Pallor, cyanosis.
• Palpation:
  • Tactile Fremitus: May be decreased due to air trapping.
  • Peripheral Perfusion: Capillary refill time (>2 seconds) may indicate dehydration or poor perfusion.
• Auscultation:
  • Wheezing: Expiratory wheezing is characteristic, often diffuse. May be biphasic in severe cases.
  • Crackles (Rales): Fine or coarse inspiratory crackles, often diffuse.
  • Prolonged Expiration: A hallmark of airway obstruction.
  • Decreased Breath Sounds: In areas of severe air trapping or atelectasis.
• Percussion:
  • Hyperresonance: Over lung fields due to air trapping/hyperinflation.

Diagnostic Approach

Diagnosis of bronchiolitis is primarily clinical, based on history and physical examination.

History Taking

• Key Questions:
  • Age of onset and current age: Crucial for typical presentation and risk assessment.
  • Symptoms: Onset, progression, duration of cough, rhinorrhea, fever, difficulty breathing.
  • Feeding and hydration: Volume consumed, frequency of wet diapers, signs of dehydration.
  • Respiratory distress signs: Observed retractions, nasal flaring, grunting, cyanosis.
  • Exposure: To sick contacts (especially those with URI symptoms), childcare attendance.
  • Risk factors: Prematurity, chronic lung disease, congenital heart disease, immunodeficiency, tobacco smoke exposure.
  • Previous episodes: History of recurrent wheezing.
  • Immunization status: Especially influenza.
• Red Flags: Indicators of severe disease or impending respiratory failure requiring urgent attention:
  • Apnea or recurrent apneic episodes (especially in infants <60 days old).
  • Persistent oxygen saturation <90-92% on room air (specific target may vary by guideline, usually <90% is threshold for oxygen therapy).
  • Severe respiratory distress (marked retractions, nasal flaring, grunting, tachypnea >70-80 breaths/min).
  • Cyanosis.
  • Lethargy, poor feeding, signs of dehydration.
  • Age <3 months, especially <6 weeks.
  • Underlying comorbidities (CHD, CLD, immunodeficiency).

Laboratory Tests

Routine laboratory testing is generally not recommended for the diagnosis of bronchiolitis. - First-Line: * Pulse Oximetry: Essential for assessing oxygenation status. A continuous reading or frequent spot checks are crucial. - Confirmatory: * Rapid Viral Diagnostic Tests (e.g., PCR for RSV, other respiratory viruses): Generally not recommended for routine diagnosis in typical bronchiolitis cases as results do not alter management. May be useful for epidemiological surveillance, cohorting patients in hospital settings to prevent nosocomial spread, or for specific research protocols. - Monitoring: * Blood Gas Analysis (Arterial or Venous): Considered in severe respiratory distress or suspected respiratory failure to assess for hypercapnia or significant hypoxemia, or for acid-base balance. * CBC with Differential: Generally not recommended unless there is strong suspicion of bacterial co-infection (e.g., high fever without clear viral source, prolonged illness, focal findings suggestive of pneumonia or sepsis). Leukocytosis is common in viral infections and does not reliably indicate bacterial infection. * Electrolytes/Glucose: If concerns for dehydration or poor oral intake; essential for IV fluid management.

Imaging

Routine chest radiography is generally not recommended for the diagnosis of bronchiolitis. - Recommended: * Chest X-ray (CXR): Not routinely recommended for typical bronchiolitis as findings are non-specific and do not usually change management. * Indications for CXR: * Severe disease not responding to supportive care. * Atypical presentation (e.g., focal findings on exam, high fever without clear source, suspicion of bacterial pneumonia, foreign body aspiration). * Clinical suspicion of underlying cardiopulmonary disease or other complications (e.g., pneumothorax, lobar collapse). * Common CXR Findings (non-specific): Hyperinflation (flattened diaphragms, increased AP diameter), peribronchial cuffing/thickening, atelectasis (especially subsegmental), or patchy infiltrates. These findings overlap with other respiratory conditions. - Advanced: * CT Scan: Very rarely indicated for bronchiolitis; reserved for highly unusual presentations, suspected chronic lung disease, or specific complications (e.g., persistent atelectasis, suspected malformation).

Management

Acute Management

The cornerstone of bronchiolitis management is supportive care. No specific antiviral treatments or bronchodilators are routinely recommended. - Immediate: * Assess Airway, Breathing, Circulation (ABCs): Rapid assessment of respiratory distress, oxygenation, and perfusion. * Oxygen Therapy: Administer supplemental oxygen if SpO2 persistently <90-92% on room air. Aim to maintain SpO2 ≥90% (AAP guideline) or ≥92% (NICE guideline). Delivery methods include nasal cannula, oxygen hood, or face mask. * Hydration: Assess hydration status. Offer frequent small amounts of oral fluids. If unable to maintain hydration orally due to tachypnea or poor feeding, consider intravenous (IV) fluids or nasogastric (NG) tube feeding. - Stabilization: * Nasal Suctioning: Gentle nasal suctioning (bulb syringe or nasal aspirator) is crucial, especially before feeding, to clear secretions and improve breathing. * Positioning: Elevate the head of the bed or position infant at a 30-45 degree angle to ease breathing. * Monitoring: Continuous pulse oximetry, respiratory rate, heart rate, work of breathing, and hydration status. * Nebulized Hypertonic Saline (3%): Use is controversial and not universally recommended. Some guidelines suggest considering for hospitalized infants, especially those <6 months, but not for outpatient management. It may reduce length of stay in some cohorts by promoting mucociliary clearance. Do not use in the emergency department for initial management. * Bronchodilators (e.g., Albuterol, Epinephrine): Not routinely recommended. A trial of a bronchodilator (e.g., nebulized albuterol or epinephrine) may be considered only for severe cases, if the infant has a history of asthma or atopy, or if there is a clear clinical response. If no improvement after one or two doses, discontinue use. Routine use is not supported by evidence and can lead to side effects without benefit. * Systemic Corticosteroids: Not recommended for routine management of acute bronchiolitis due to lack of demonstrated benefit in reducing severity or duration of illness. * Antibiotics: Not recommended unless there is clear evidence or strong suspicion of bacterial co-infection (e.g., clinical signs of bacterial pneumonia, otitis media, or positive bacterial culture). * Chest Physiotherapy: Not routinely recommended. Evidence does not support its efficacy and it may cause distress. - Emergency: * High-Flow Nasal Cannula (HFNC): Increasingly used in moderate-to-severe bronchiolitis. Delivers warmed, humidified, high-flow air/oxygen, which can generate positive airway pressure and flush dead space, reducing work of breathing and potentially avoiding escalation to mechanical ventilation. * Continuous Positive Airway Pressure (CPAP): May be considered if HFNC is insufficient or unavailable, particularly for infants with significant respiratory distress and hypoxemia. * Mechanical Ventilation: Reserved for infants with impending respiratory failure (e.g., persistent apnea, severe hypercapnia, refractory hypoxemia, exhaustion). * Intravenous Immunoglobulin (IVIG): Not indicated for bronchiolitis.

Chronic Management

Bronchiolitis is an acute illness. Chronic management focuses on addressing potential long-term sequelae. - Pharmacological: * No specific chronic pharmacological agents for bronchiolitis itself. * Corticosteroids/Bronchodilators: Long-term use of inhaled corticosteroids or bronchodilators is not recommended to prevent recurrent wheezing or asthma after bronchiolitis. - Non-pharmacological: * Environmental Control: Avoiding exposure to tobacco smoke is paramount, as it increases the risk of recurrent wheezing and asthma. * Breastfeeding: Encourage continued breastfeeding. * Monitoring for Recurrent Wheezing: Counsel parents that some infants, particularly those hospitalized for bronchiolitis, may develop recurrent wheezing or asthma later in childhood. - Monitoring: * Long-term follow-up: No specific long-term follow-up for bronchiolitis itself. Follow up for general well-child care and monitor for signs of recurrent wheezing or development of asthma.

Treatment Algorithms

• First-Line:
  1. Clinical Diagnosis: Based on history and physical exam.
  2. Severity Assessment: Assess respiratory distress (rate, work of breathing), oxygen saturation, hydration status.
  3. Supportive Care:
     • Nasal suctioning.
     • Hydration (oral, NG, or IV fluids as needed).
     • Oxygen therapy for SpO2 <90-92%.
     • Fever management.
  4. Discharge vs. Hospitalization Criteria:
     • Discharge: SpO2 ≥90% on room air, adequate oral intake, minimal respiratory distress, caretaker comfortable managing at home. Provide clear instructions on worsening signs.
     • Hospitalization:
       • Persistent SpO2 <90-92% in room air.
       • Significant respiratory distress (e.g., tachypnea >60 breaths/min with retractions, nasal flaring).
       • Apnea.
       • Inability to maintain hydration orally (signs of dehydration).
       • Age <2-3 months.
       • Underlying comorbidities (prematurity, CHD, CLD, immunodeficiency).
       • Caregiver unable to provide adequate care at home.
• Second-Line (for hospitalized patients, after initial supportive care):
  1. Consider HFNC for increasing respiratory distress or oxygen requirements.
  2. Consider nebulized hypertonic saline (3%) in hospitalized infants, especially those <6 months, but recognize controversial and not universally effective.
  3. Consider a single trial of bronchodilator (albuterol or epinephrine) for severe cases, particularly if strong history of atopy/asthma, and discontinue if no clear clinical benefit.
• Refractory Cases:
  • Progressive respiratory failure despite HFNC/CPAP: Consider escalation to mechanical ventilation.
  • Rule out other diagnoses or complications (e.g., bacterial pneumonia, aspiration, foreign body, underlying cardiac disease).

Complications

• Common:
  • Dehydration: Due to decreased oral intake and increased insensible fluid losses from tachypnea and fever.
  • Secondary Bacterial Infections:
    • Otitis Media: Common, especially during or after bronchiolitis.
    • Bacterial Pneumonia: Less common, but possible, indicated by persistent high fever, worsening respiratory status, or focal lung findings.
• Serious:
  • Respiratory Failure: Leading to need for ventilatory support.
  • Apnea: Especially in young infants, can be life-threatening.
  • Pneumothorax/Pneumomediastinum: Rare, due to severe air trapping and rupture of alveolar walls.
• Long-term:
  • Recurrent Wheezing/Asthma: Infants, especially those with severe bronchiolitis or a history of atopy/allergies, have an increased risk of developing recurrent wheezing or asthma later in childhood. This relationship is complex and not fully understood.

Prognosis

• Factors:
  • Age: Younger infants (especially <6-12 weeks) are at higher risk for severe disease, hospitalization, and complications like apnea.
  • Underlying Medical Conditions: Prematurity, congenital heart disease, chronic lung disease, and immunodeficiency are significant risk factors for severe disease and poorer outcomes.
  • Specific Viral Etiology: RSV and human metapneumovirus are often associated with more severe disease than rhinovirus.
• Survival: Overall prognosis is excellent. Mortality rates are very low (<0.1%) in healthy full-term infants. Mortality is higher in infants with significant underlying comorbidities.
• Quality of Life: Most infants recover completely without long-term sequelae. However, a significant proportion (20-40%) may experience recurrent wheezing for several years, which may or may not evolve into asthma. Hospitalization for bronchiolitis is associated with increased healthcare utilization in the first year of life.

Prevention

• Primary: Aimed at reducing exposure to viruses and strengthening host immunity.
  • Hand Hygiene: Frequent handwashing with soap and water (or alcohol-based hand rub) by caregivers and anyone in contact with infants.
  • Avoid Sick Contacts: Limit exposure of infants to individuals with respiratory symptoms, especially during peak viral season.
  • Avoid Tobacco Smoke Exposure: Counsel parents about the importance of a smoke-free environment.
  • Breastfeeding: Encourage exclusive breastfeeding for at least 6 months, as it provides passive immunity.
  • Vaccination:
    • Influenza Vaccine: Recommended for all individuals ≥6 months of age, including pregnant women, to protect infants through maternal antibodies.
    • Maternal RSV Vaccine: New options becoming available for pregnant women (e.g., Abrysvo) to provide passive immunity to infants.
    • Monoclonal Antibodies for RSV Prevention:
      • Palivizumab (Synagis®): Monthly intramuscular injection given during RSV season to high-risk infants (e.g., premature infants born at ≤29 weeks 6 days gestation, infants with hemodynamically significant congenital heart disease, chronic lung disease of prematurity requiring medical support, severe immunodeficiency). Specific criteria vary by guideline.
      • Nirsevimab (Beyfortus™): A single dose long-acting monoclonal antibody approved for all infants <8 months of age entering their first RSV season and for children 8-19 months of age who are at increased risk (e.g., chronic lung disease, severe immunodeficiency) entering their second RSV season. It offers broad protection and is preferred over palivizumab due to its longer half-life and single-dose convenience.
• Secondary: Early detection and intervention. Focus on prompt diagnosis and supportive care to prevent progression to severe disease.
• Tertiary: Preventing complications. Timely hospitalization for infants meeting criteria, vigilant monitoring, and appropriate supportive care.

Special Populations

• Pediatric:
  • Neonates and Young Infants (<6-12 weeks): Higher risk for severe disease, apnea, and respiratory failure. May present with atypical symptoms like lethargy or poor feeding without significant cough/wheeze. Close monitoring and lower threshold for hospitalization.
  • Infants with Pre-existing Conditions:
    • Prematurity: Especially those with chronic lung disease of prematurity (bronchopulmonary dysplasia). Have underdeveloped lungs and compromised respiratory mechanics, leading to more severe and prolonged illness.
    • Congenital Heart Disease (CHD): Especially hemodynamically significant lesions (e.g., large left-to-right shunts, pulmonary hypertension). Increased risk of heart failure exacerbation, pulmonary edema, and respiratory failure.
    • Immunodeficiency: Impaired ability to clear viral infections, leading to more severe and prolonged illness.
    • Neuromuscular Disorders: Impaired cough reflex and airway clearance, increasing risk of aspiration and respiratory compromise.
• Geriatric: Bronchiolitis is primarily a pediatric disease. Similar acute viral lower respiratory tract infections in adults are often termed bronchitis or pneumonia. RSV can cause significant morbidity and mortality in older adults, presenting as bronchitis or pneumonia.
• Pregnancy: Not applicable to bronchiolitis as a primary disease. However, maternal RSV infection during pregnancy can lead to severe illness in the mother. Vaccination strategies target pregnant women to confer passive immunity to their infants.
• Comorbidities: See "Pediatric" section above. Management requires heightened vigilance, lower thresholds for hospitalization, and close monitoring for decompensation of their underlying condition. RSV prophylaxis with palivizumab or nirsevimab is critical for specific high-risk groups.

Clinical Pearls

• Diagnostic:
  • Clinical Diagnosis is Key: Do not rely on laboratory tests or imaging for routine diagnosis. Bronchiolitis is a clinical diagnosis based on age, season, and characteristic symptoms/signs.
  • Distinguish from Asthma: In infants <12 months, it is usually bronchiolitis. While both cause wheezing, bronchiolitis is a first-time event, often with URTI prodrome, and bronchodilators typically have limited efficacy.
  • Consider Apnea Equivalents: In very young or premature infants, apnea or decreased feeding may be the primary manifestation.
• Treatment:
  • Supportive Care is Paramount: Focus on oxygen, hydration, and airway clearance (nasal suctioning). These are the only consistently beneficial interventions.
  • Avoid Unnecessary Interventions: Resist the urge to prescribe bronchodilators, corticosteroids, or antibiotics routinely. They offer no consistent benefit and can cause harm or delay effective care.
  • Nasal Suctioning is Highly Effective: Teach parents how to perform gentle but effective nasal suctioning, especially before feeds.
  • Manage Expectations: Educate parents that bronchiolitis is a self-limiting viral illness that can last 2-3 weeks, with cough potentially lingering longer.
• Pitfalls:
  • Over-reliance on CXR: Routine CXR often leads to incidental findings (e.g., atelectasis) that do not change management but may prompt unnecessary antibiotic use or further investigation.
  • Unnecessary Viral Testing: While helpful for cohorting in hospitals, routine viral testing does not alter individual patient management and adds cost.
  • Empiric Antibiotics: Starting antibiotics without clear evidence of bacterial co-infection contributes to antibiotic resistance and patient harm.
  • Discharge Too Soon: Ensure SpO2 is stable on room air, feeding is adequate, and caregivers are confident before discharge.

Recent Updates

• Guidelines: Recent guidelines from major organizations (e.g., American Academy of Pediatrics (AAP) 2014, updated 2021; National Institute for Health and Care Excellence (NICE) 2015, updated 2021) strongly emphasize:
  • No routine use of bronchodilators, systemic corticosteroids, or antibiotics.
  • No routine use of chest physiotherapy.
  • No routine viral testing (e.g., RSV PCR).
  • No routine chest X-rays.
  • Emphasis on supportive care: hydration, oxygen, and nasal suctioning.
  • Increased use of High-Flow Nasal Cannula (HFNC) as a non-invasive respiratory support strategy in hospitalized infants.
  • Hypertonic saline may be considered in hospitalized infants but not for outpatient management or in the ED.
• Evidence:
  • Continued research confirms the limited efficacy of bronchodilators and corticosteroids in most cases of bronchiolitis.
  • Growing evidence supports the role of HFNC in reducing the need for invasive ventilation in moderate to severe cases.
• Controversies:
  • Role of Hypertonic Saline: While some studies show modest benefits in reducing length of stay for hospitalized infants, others show no significant benefit. Its precise role and ideal patient population remain debated.
  • Predicting Asthma: The long-term relationship between bronchiolitis (especially RSV) and the development of recurrent wheezing/asthma remains an active area of research.
  • Optimal Timing and Dosing of HFNC: Ongoing studies are refining parameters for HFNC use in bronchiolitis.
  • Nirsevimab vs. Palivizumab: With the widespread availability of nirsevimab, the role of palivizumab is narrowing to a very specific, small group of high-risk infants who may not be eligible for or received nirsevimab.

Key References

• Guidelines:
  • American Academy of Pediatrics (AAP) Clinical Practice Guideline: Ralston SL, et al. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. Pediatrics. 2014 Nov;134(5):e1474-e1502. (Note: A focused update on prevention and new therapies is available, but the core management principles remain.)
  • National Institute for Health and Care Excellence (NICE) Guideline [NG9]: Bronchiolitis in children: diagnosis and management. Published August 2015, last updated March 2021. Available at: https://www.nice.org.uk/guidance/ng9
• Studies:
  • Semler MW, et al. A Multicenter, Randomized Trial of High-Flow Nasal Cannula in Infants with Bronchiolitis. N Engl J Med. 2022;387(18):1661-1671. (Example of a recent trial on HFNC)
  • Drysdale SB, et al. Nirsevimab for Prevention of RSV in Infants and Young Children: A Global Perspective on the New Monoclonal Antibody. Clin Infect Dis. 2023 Feb 8;76(3):589-598. (Review on nirsevimab)
• Reviews:
  • Mecklin M, et al. Bronchiolitis: A Review. JAMA. 2022 Dec 13;328(22):2251-2260.
  • Rodrigo GJ, Castro-Rodríguez JA. Bronchodilators for bronchiolitis: a systematic review with meta-analysis. Pediatr Pulmonol. 2018 Jan;53(1):127-133.

Final Note: Clinical practice guidelines evolve. Clinicians should always refer to the most current versions of guidelines from authoritative bodies and integrate them with their clinical judgment and patient-specific factors.